Koller WC, Fields JZ, Gordon JH, Perlow MJ (September 1986). „Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug”. Neuropharmacology25 (9): 973–9. DOI:10.1016/0028-3908(86)90190-5. PMID3774130.
Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J (1987). „A double-blind evaluation of ciladopa in Parkinson's disease”. Movement Disorders : Official Journal of the Movement Disorder Society2 (3): 211–7. DOI:10.1002/mds.870020308. PMID3332914.
Koller WC, Fields JZ, Gordon JH, Perlow MJ (September 1986). „Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug”. Neuropharmacology25 (9): 973–9. DOI:10.1016/0028-3908(86)90190-5. PMID3774130.
Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J (1987). „A double-blind evaluation of ciladopa in Parkinson's disease”. Movement Disorders : Official Journal of the Movement Disorder Society2 (3): 211–7. DOI:10.1002/mds.870020308. PMID3332914.
Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M (May 1987). „Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa”. Neurology37 (5): 863–5. PMID3574692.
Lang AE (August 1987). „Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine"”. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques14 (3 Suppl): 474–82. PMID3315148.